Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.

Mengdie Zhang,Kai Xu,Yingtao Lin,Chongchong Zhou,Yuwen Bao,Lingli Zhang,Xin Li

Frontiers in immunology（2023）

Cited 0|Views4
No score
Abstract
At a WTP threshold of $37,654 per QALY, TC was cost-effective compared to PC for patients with advanced NSCLC in China.
More
Translated text
Key words
toripalimab,PD-1,cost-effectiveness,partitioned survival model,advanced non-small cell lung cancer (advanced NSCLC),chemothearpy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined